InnoCan Pharma Corporation (CSE:INNO) has announced that cell and gene therapy specialist Professor Daniel Offen had been appointed to its scientific advisory committee following the firm's tie-up with Tel Aviv University company, Ramot.
Professor Offen works at the Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Sagol School of Neuroscience at Tel Aviv University.
READ: InnoCan Pharma Corp announces tie-up with Tel Aviv University for new treatment for coronavirus pandemic
"We, InnoCan Pharma and the University of Tel Aviv are joining the forces now to develop, what we expect to be, a revolutionary approach to fight multiple diseases," Professor Offen said in a statement.
"Based on my personal experience, I feel that our approach treating (coronavirus) COVID-19 disease with a combination of exosomes and CBD molecules hold a great potential."
He also noted that Exosomes research was a relatively new field in the stem cell sector. Exosomes are small particles created when stem cells are multiplied. They can act as "homing missiles", targeting specific damaged organs and have an important role in cell-to-cell communication.
Last month, Innocan revealed that CBD-loaded Exosomes hold the potential to provide anti-inflammatory properties and help infected lung cells to recover.
Professor Offen studied molecular biology at the Weizmann Institute of Science, Israel and went on to the Albert Einstein College of Medicine in New York as a post-doctoral fellow. He has published over 200 articles, review papers and book chapters and had file over 30 granted patents.
Contact the author at [email protected]